18F BMS 986327
Alternative Names: 18F-BMS-986327Latest Information Update: 28 Mar 2025
At a glance
- Originator Bristol-Myers Squibb
- Class Diagnostic agents; Imaging agents; Radiopharmaceutical diagnostics
- Mechanism of Action Positron-emission tomography enhancers; Radionuclide imaging enhancers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Idiopathic pulmonary fibrosis
Most Recent Events
- 28 Mar 2025 No recent reports of development identified for phase-I development in Idiopathic-pulmonary-fibrosis(Diagnosis) in USA
- 15 Mar 2023 18F BMS 986327 is still in Phase-I trials for Idiopathic pulmonary fibrosis (Diagnosis) in USA (unspecified route) (NCT04069143)
- 28 Oct 2022 No recent reports of development identified for phase-I development in Idiopathic-pulmonary-fibrosis(Diagnosis) in USA